In only a brief period of time, the cannabis industry has achieved remarkable progress, bringing to market safer, more intelligent product offerings, backed by research and designed to not only enhance but transform the consumer experience. Science and biotechnology companies are increasingly breaking down barriers, fighting the stigma, and making important strides toward gaining widespread acceptance of marijuana as a legitimate medical tool and, more specifically, as a trusted alternative to harmful and addictive prescription opiates.Read More
Chief Science Officer, Dr. Kaufman makes some thoughtful arguments about the speed of transdermal delivery.
However, these mainstream methods of consuming and administering marijuana are potentially problematic for a number of reasons. Fortunately, innovative new administration methods that deliver cannabinoids through the skin—using transdermals—or through the mucosa in the nose and mouth—using intranasal and intraoral products—are on the rise, offering promising solutions to the common issues associated with traditional cannabis delivery.Read More
Dear Valued Shareholders,
I would like to take this opportunity to outline the details of a significant milestone for NanoSphere Health Sciences and how this will impact the future of the company. We have been granted our landmark patent for the NanoSphere Delivery System™, which means we now officially have ownership of the biggest advancement in non-invasive medical delivery in over 25 years. A major thank you is in order to everyone who has come on this journey with us, especially those who have been here since the very beginning—from the challenging years of R&D through the pivotal point of commercialization to now, as we realize this new reality and lay the foundation for the bright future of this business.Read More
Landmark patent marks most significant advancement in over 25 years for non-invasive medical delivery system
Denver (March 27, 2018) – NanoSphere Health Sciences Inc (CSE: NSHS) (OTC: NSHSF) is pleased to announce that its flagship subsidiary, NanoSphere Health Sciences, LLC, has been granted Patent No. 9,925.149—which covers the core technology behind the production of the NanoSphere Delivery System™—by the United States Patent and Trademark Office.Read More
Evolve Formulas’ Transdermal NanoSerum™ Continues to Expand
DENVER (March 7, 2018) – NanoSphere Health Sciences Inc. (CSE: NSHS/ OTC: NSHSF) cannabis product brand Evolve Formulas is now stocked in over 100 dispensaries throughout Colorado. The company’s pioneering product, Transdermal NanoSerum™, uses the NanoSphere Delivery System™ developed by the biotechnology firm to allow cannabis to enter systemic circulation within ten minutes for fast-acting, effective relief from pain, inflammation and anxiety. This milestone comes on the back of continuous growth, with the company recently signing a licensing agreement in California.Read More
20 Dose-Dispenser Provides Discrete and Hassle-Free Option for Evolve Customers
DENVER (DATE) – Back by popular demand, the 5ml Transdermal NanoSerum™ pen is now available in more than 90 dispensaries throughout Colorado. This compact product size contains 20 doses of NanoSerum™, each with 10mg of THC. The game-changing Evolve Formulas product immediately penetrates the skin following application to deliver direct-focused relief from pain, inflammation and anxiety.Read More
Innovative Biotech Company Teams Up With Dispensary and Charity Partners for Community Event
Denver (Feb 26, 2018) - Evolve Formulas supported one of Denver’s most vulnerable populations last week through a unique charity initiative. A Kitchen One-For-One food truck served up a variety of delicious menu items to Evolve customers at the Lightshade - Peoria dispensary. For every meal provided to Lightshade employees and customers, a meal will go to those in need. Approximately 800 meals will be provided to homeless members of the local community as a result of the initiative on Saturday, March 3.Read More
DENVER, Dec. 4, 2017 /PRNewswire/ -- NanoSphere Health Sciences Inc. (CSE: NSHS) ("NanoSphere") (formerly Corazon Gold Corp.) is pleased to announce a name change and listing on the Canadian Securities Exchange (the "CSE"), effective today. NanoSphere's shares will commence trading tomorrow, December 5, 2017, under the symbol "NSHS".Read More
Corazon Gold Corp. (the “Company”) and NanoSphere Health Sciences, LLC (“NanoSphere”) are pleased to announce the closing of the Company’s private placement (the “Offering”) for gross proceeds of $5,905,685, and the completion of the Company’s acquisition (the “Acquisition”) of NanoSphere. Based upon the CSE’s conditional listing approval, the Company will make its final submission for CSE listing in short order, and concurrently with its listing on the CSE will change its name to “NanoSphere Health Sciences Inc.” and effect a de-listing from the TSX Venture Exchange.Read More
NanoSerum™ is a fast-acting transdermal formula with the patent-pending NanoSphere Delivery System™ for rapid absorption across the skin membrane.
Evolve Formulas, LLC, today announced the launch of their first cannabis product NanoSerum™. NanoSerum™ is the world’s first and only clinically-tested transdermal cannabis product to relieve pain and anxiety in mere minutes compared to hours with other alternative delivery methods.Read More
By: David Sutton
Current delivery methods are inferior, but great things are coming.
Colorado and Washington became the first states to legalize cannabis for recreational use in 2012, since then, six others have followed suit, and more are sure to come. The legislation shift has been an economic boon. However, with all the positive results of legalization, we also regularly hear horror stories in the news about what happens when people mistakenly overindulge and end up in the emergency room.Read More